The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pain Res.
Sec. Cancer Pain
Volume 6 - 2025 |
doi: 10.3389/fpain.2025.1481245
Underutilized treatments for patients with refractory cancer pain: A qualitative study assessing the use of intrathecal drug delivery devices in the United Kingdom compared to alternative treatments in cancer pain management
Provisionally accepted
Rik Buschman 1,2*
Victoria Barnosky 3*
Matthew R D Brown 4
Somnath Bagchi 5 Remy Blain 6 Demir Husejnovic Husejnovic 6 Sandra Johnson 6 Meredith Mackworth-Praed 6- 1 Other, Eindhoven, Netherlands
- 2 Medtronic (Netherlands), Heerlen, Netherlands
- 3 Robert Morris University, Pittsburgh, United States
- 4 Pain Medicine Department, The Royal Marsden Hospital, London, United Kingdom
- 5 Chronic Pain Unit, Derriford Hospital, Plymouth, United Kingdom
- 6 Suazio Consulting, Antwerp, Belgium
This research aims to better delineate how intrathecal drug delivery systems (IDDS) are incorporated into the oncology care continuum and highlight the need for further awareness of interventional options for pain management of cancer patients in the United Kingdom. The study focuses on exploring the knowledge, perspectives, and experiences of healthcare professionals regarding IDDS as a treatment option for managing chronic refractory pain in cancer patients.A thematic coding using inductive analysis was employed to achieve the research objectives.Semi-structured interviews were conducted with 18 healthcare professionals in various specialties, including oncology, neurosurgery, pain management, and palliative care. The interviews were transcribed, and a two-phased qualitative inductive coding approach was used to analyze the data.The findings of the study revealed four major themes: Education, Barriers & Benefits, Technical & Administrative, and Patient-Centered Care. The theme of Education highlighted the need for increased knowledge and awareness of IDDS among healthcare professionals. Barriers & Benefits encompassed concerns about infection risk, suitability for patients with a short life expectancy, and the challenges and advantages of IDDS use. The Technical & Administrative theme addressed cost considerations, device management, and the need for improved guidelines. Patient-Centered Care emphasized the importance of involving patients in decisionmaking and considering their physical and emotional well-being throughout the treatment pathway.This research identifies several areas of unmet need in the management of refractory pain in cancer patients, including the development of more inclusive guidelines, greater awareness among clinicians and patients, and the role of medical technology companies in supporting effective pain management. The findings underscore the impact of IDDS on improving pain control and highlight the potential importance of early intervention and comprehensive pain management in influencing the trajectory of oncological diseases.
Keywords: Cancer, Refractory pain, Pain interventions, qualitative study, Intrathecal drug delivery
Received: 15 Aug 2024; Accepted: 31 Jan 2025.
Copyright: © 2025 Buschman, Barnosky, Brown, Bagchi, Blain, Husejnovic, Johnson and Mackworth-Praed. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Rik Buschman, Other, Eindhoven, Netherlands
Victoria Barnosky, Robert Morris University, Pittsburgh, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.